Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy

Internal Medicine Journal

Volumn 43, Issue 1, 2013, Pages 73-76

  Gao, H F ^a   Liang, Y ^a   Zhou, N N ^a   Zhang, D S ^a   Wu, H Y ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Aprepitant; Chemotherapy induced nausea and vomiting; Multiple day cisplatin; Palonosetron

Indexed keywords

APREPITANT; CISPLATIN; DEXAMETHASONE; PALONOSETRON;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CONSTIPATION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HEADACHE; HICCUP; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; SOLID TUMOR; TREATMENT RESPONSE;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CONSTIPATION; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FATIGUE; FEMALE; HEADACHE; HICCUP; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; MORPHOLINES; NAUSEA; NEOPLASMS; PROSPECTIVE STUDIES; QUINUCLIDINES; RECEPTORS, NEUROKININ-1; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; VOMITING; YOUNG ADULT;

EID: 84872584635     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2011.02637.x     Document Type: Article

References (20)

1. Griffin AM, Butow PN, Coates AS, Childs AM, Ellis PM, Dunn SM etal. On the receiving end V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 1996; 7: 189-195.
2. Hesketh PJ, Harvey WH, Harker WG, Beck TM, Ryan T, Bricker LJ etal. A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin induced emesis. J Clin Oncol 1994; 12: 596-600.
3. Geling O, Eichler H-G. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemo-therapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 2005; 23: 1289-1294.
4. Stoltz R, Cyong JC, Shah A, Parisi S. Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects. J Clin Pharmacol 2004; 44: 520-531.
5. Wong EH, Clark R, Leung E, Loury D, Bonhaus DW, Jakeman L etal. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br J Pharmacol 1995; 114: 851-859.
6. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R etal. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003; 21: 4112-4119. doi: 10.1200/JCO.2003.01.095.
7. Grote T, Hajdenberg J, Cartmell A, Ferguson S, Ginkel A, Charu V. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone and aprepitant. J Support Oncol 2006; 4: 403-408.
8. Grunberg SM, Dugan M, Muss H, Wood M, Burdette-Radoux S, Weisberg T etal. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support Care Cancer 2009; 17: 589-594.
9. Longo F, Mansueto G, Lapadula V, De Sanctis R, Quadrini S, Grande R etal. Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 2010; 19; 1159-1164.
10. Roila F, Hesketh PJ, Herrstedt J. Prevention of chemotherapy and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006; 17: 20-28.
11. Fox SM, Einhorn LH, Cox E, Powell N, Abdy A. Ondansetron versus ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy. J Clin Oncol 1993; 11: 2391-2395.
12. Weissbach L. Ondansetron. Lancet 1991; 338: 753-754.
13. Jordan K, Kinitz I, Voigt W, Behlendorf T, Wolf HH, Schmoll HJ. Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy. Eur J Cancer 2009; 45: 1184-1187.
14. de Wit R, Schmitz PI, Verweij J, de Boer-Dennert M, de Mulder PH, Planting AS etal. Analysis of cumulative probabilities shows that the efficacy of 5-HT3 antagonist prophylaxis is not maintained. J Clin Oncol 1996; 14: 644-651.
15. Einhorn LH, Brames MJ, Dreicer R, Nichols CR, Cullen MT Jr, Bubalo J. Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer 2007; 15: 1293-1300.
16. Moore S, Tumeh J, Wojtanowski S, Flowers C. Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy. Value Health 2007; 10: 23-31.
17. Cubeddu LX, Hofmann IS, Fuenmayor NT, Malave JJ. Changes in serotonin metabolism in cancer patients: its relationship to nausea and vomiting induced by chemotherapeutic drugs. Br J Cancer 1992; 66: 198-203.
18. Cubeddu LX, Hoffmann IS. Participation of serotonin on early and delayed emesis induced by initial and subsequent cycles of cisplatinum-based chemotherapy: effects of antiemetics. J Clin Pharmacol 1993; 33: 691-697.
19. De Wit R, Van Den Berg H, Burghouts J, Nortier J, Slee P, Rodenburg C etal. Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles. Br J Cancer 1998; 77: 1487-1491.
20. Blijham GH. Does granisetron remain effective over multiple cycles? Eur J Cancer 1992; 28A (Suppl 1): S17-S21.